The HCPLive Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.
October 8th 2024
An interim analysis of the PRO-SPIRIT study compared outcomes at 3 months after starting new treatments for psoriatic arthritis.
Collaborating Across the Continuum™: The Role of Multidisciplinary Care in the Management of Patients with Exocrine Pancreatic Insufficiency
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
October 26, 2024
Register Now!
6th Annual Advanced Practice Collaborative
View More
SimulatED™: Personalizing Treatment Choices to Achieve Glycemic and Weight Management Goals
View More
Cases and Conversations™: Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis
November 18, 2024
Register Now!
Shaping the Management of COPD with Biologic Therapy
View More
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Expert Illustrations & Commentaries™: Exploring the Role of Novel Agents for the Management of IgA Nephropathy
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Clinical ShowCase™: Finding the Best Path Forward for Patients with COPD
View More
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age
View More
Clinical ShowCase™: Forming a Personalized Treatment Plan for a Patient With ANCA-Associated Vasculitis
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
Patient, Provider & Caregiver Connection™: Implementing an Effective Management Plan to Improve Outcomes in IgA Nephropathy
View More
Motion Tests Essential for an Osteoarthritis Diagnosis
January 28th 2020Simple hip motion tests and observing for pain during that motion were helpful in identifying patients most likely to have hip osteoarthritis on plain radiography, say researchers recently writing in the Journal of the American Medical Association.
High Dose Flu Shot Best for Rheumatoid Arthritis
January 28th 2020In patients with seropositive rheumatoid arthritis, high-dose trivalent inactivated influenza vaccine (HD-TIV) is safe and more immunogenic than standard-dose quadrivalent influenza vaccine (SD-QIV), say researchers writing in The Lancet Rheumatology.
Probiotics Protect Against Lumbar Spine Bone Loss in Early Menopause
January 28th 2020Probiotic supplementation using a mix of three Lactobacillus strains naturally occurring in the human gut microbiota protects against lumbar spine bone loss in healthy, early postmenopausal women, say researchers recently writing in The Lancet Rheumatology.
Lupus Trial for Anifrolumab Gets a Second Look
January 24th 2020Anifrolumab, a potential new treatment for systemic lupus erythematosus (SLE), was given a second look in a clinical trial published in the New England Journal of Medicine this month. This time, the results look promising. Learn more about the trial in this slideshow.
9 Key Facts About CVD in Rheumatoid Arthritis
January 22nd 2020Rheumatoid arthritis patients have an increased risk of developing cardiovascular disease, yet rheumatologists and primary care physicians who treat RA patients sometimes miss the signs and symptoms of CVD in their patients. Learn more in this slideshow.
RA Quiz: How well does upadacitinib fare as RA treatment?
January 17th 2020The JAK inhibitor upadacitinib was approved last August for the treatment of moderate to severe rheumatoid arthritis. In this quiz, we focus on findings from a recent phase three clinical trial that tested different doses of this new oral medication. Test your knowledge of upadacitinib in this quiz.
RA News Roundup: CVD-Related Deaths
January 17th 2020In this slideshow, we feature results from some noteworthy rheumatoid arthritis studies that were recently published: improved patient-reported outcomes in refractory rheumatoid arthritis with use of a JAK inhibitor, mortality risk with coronary microvascular dysfunction similar in rheumatoid arthritis and diabetes, prescriber preference affects the length of time a patient takes a conventional synthetic DMARD before switching to a biologic DMARD, and more.
Upadacitinib May Improve Patient-Reported Outcomes in Refractory RA
January 16th 2020Treatment with the recently approved oral, selective JAK-1 inhibitor upadacitinib (Rinvoq, AbbVie) resulted in significant improvements in various patient-reported outcomes among individuals with rheumatoid arthritis who have had inadequate responses to biologic DMARDs, researchers report in Arthritis Research & Therapy.
Apremilast Continues to Show Viability as Monotherapy
January 16th 2020Psoriatic arthritis patients with moderate disease activity were more likely to reach treatment targets or low disease activity at week 52 with apremilast (Otezla, Celgene) than patients with high disease activity, researchers report in the January 7 issue of Arthritis Care and Research.
Spondyloarthritis News Roundup
January 14th 2020Turkish researchers are reporting the results of small study that shows too much vitamin D may be associated with the severity of in disease ankylosing spondylitis patients. Learn more about this and other recent findings from spondylarthritis research in today's news roundup.
Drug and Nondrug Approaches for Treating Osteoarthritis
January 10th 2020Updated treatment guidelines for hand, hip and knee osteoarthritis have been issued. In this slideshow, we highlight recommendations for the use (or not) of drug and nondrug treatments. These include strong recommendations for standard treatment options, such as weight loss and Tai Chi, and strong recommendations against treatments with pharmacologicals, such as glucosamine and chondroitin sulfate (except for hand osteoarthritis). Learn more in this slideshow.
Tai-Chi, Topical Capsaicin Among the New Treatment Recommendations for Osteoarthritis
January 9th 2020The American College of Rheumatology (ACR), in partnership with the Arthritis Foundation, has issued treatment guidelines for osteoarthritis of the hand, hip and knee. This is the first update since 2012.
Monitor NSAID GI Risk in Ankylosing Spondylitis, Study Warns
January 9th 2020In patients with ankylosing spondylitis receiving treatment with non‐steroidal anti‐inflammatory drugs (NSAIDs), timely therapeutic strategies should be implemented in order to manage gastrointestinal risk, say researchers recently writing in the International Journal of Rheumatic Disease.
11 Considerations for Tapering Biologic Therapy in Inflammatory Arthritis
January 7th 2020In a review published last month in Autoimmunity Reviews, British researchers outline factors physicians should consider when contemplating tapering biologic therapies in patients with inflammatory arthritis. How best to wean patients from biologic therapy is an issue that comes up more frequently these days as patients increasingly achieve remission or low disease activity. In this slideshow, we highlight considerations physicians may want to consider in treating these patients.
Turning Points in Research for Systemic Lupus in 2019
December 24th 2019In this slideshow, we feature the lupus stories that resonated most with our readers in 2019: Lupus patients are increasingly turning to opioid use to control pain, a study that shows anifrolumab may be the next belimumab for lupus, patients are turning to pill splitting to keep costs down, among others.
FDA Approves First-Ever Treatment for Pediatric GPA, MPA
December 20th 2019The U.S. Food and Drug Administration has approved rituximab (Rituxan, Genentech) for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children 2 years of age and older in combination with glucocorticoids, to fulfil an unmet medical need for these rare and serious diseases in children.
Opioid Use in Systemic Lupus Erythematosus is on the Rise
December 20th 2019Nearly one third of patients with systemic lupus erythematosus use prescription opioids, with around two thirds of those using opioids for more than a year, while emergency department use is associated with increased prescription opioid use, say researchers writing in Morbidity and Mortality Weekly Report in Septmeber.